Related Experiment Videos
Intravesical chemotherapy. Treatment selection, techniques, and results
1Harvard Program in Urology (Longwood Area), Harvard Medical School, Boston, Massachusetts.
The Urologic Clinics of North America
|August 1, 1992
Summary
Intravesical chemotherapy can reduce superficial bladder cancer recurrence but doesn't prevent muscle-invasive tumors. Further randomized studies are needed to optimize treatment timing and dosage for better outcomes.
Area of Science:
- Oncology
- Urology
Background:
- Superficial bladder cancer frequently recurs, necessitating effective management strategies.
- Current treatments aim to ablate tumors and prevent recurrence.
Purpose of the Study:
- To review the role of intravesical chemotherapy in managing superficial bladder cancer.
- To identify areas requiring further research for optimizing treatment protocols.
Main Methods:
- Review of existing literature on intravesical chemotherapy for superficial bladder cancer.
- Analysis of factors influencing therapeutic decisions, including stage, grade, and multicentricity.
Main Results:
- Intravesical chemotherapy reduces recurrence rates of superficial tumors.
- Evidence is lacking to confirm a reduction in the incidence of muscle-invasive tumors.
- Optimal dosage, schedules, and timing post-resection require further investigation.
Conclusions:
- Intravesical chemotherapy is a valuable tool for managing superficial bladder cancer recurrence.
- Randomized clinical trials are essential to clarify optimal treatment strategies and improve patient outcomes.